Osteoarthritis of the hip joint treated with total hip replacement
Conditions
Interventions
Trade Name: Bonviva
Product Name: Bonviva
Pharmaceutical Form: Spot-on solution
CAS Number: 0
Other descriptive name: IBANDRONIC ACID MONOSODIUM SALT, MONOHYDRATE
Concentration unit: mg/ml milligram(s
Sponsors
Department of Orthopaedic Surgery University Hospital Linköping
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients 50-65 years of age with primary osteoarthritis of the hip that are planned for total hip arthroplasty. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Osteoporosis. Treatment with coticosteroids. Treatment with drugs that influence bone metabolism e.g.bisphosphonates, cytostatic drugs, anticonvulsive drugs. Osteomalacia, malignant disease, bonemetastases, osteogenesis imperfecta, dysplastic fibrosis, hyperparathyroidisim, hyperthyroidism, abnormal kidney function defined as elevated serum-kreatinin. Liver failure. Gastric ulceration within the last year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To Investigate if local treatment of the bonebed with bisphosphonate solution prior to fixation of the acetabular component of a cemented hip prosthesis decreases the risk for future loosening of the prosthesis.;Secondary Objective: ;Primary end point(s): Local treatment of the acetabular bone bed with bisphosphonate drugs results in less resorption of the periprosthetic bone and consequently in a more stabile fixation. End Point: Radiostereometric Analysis at 2 years post surgery. | — |
Countries
Sweden
Outcome results
None listed